NCO-06PREDICTING FACTORS OF BEVACIZUMAB EFFICACY IN THE PATIENTS WITH RECURRENT GLIOBLASTOMA

Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab.

Neurocognitive decline is a frequent adverse effect of glioblastoma. Antitumor therapies that are efficacious, as measured by traditional endpoints such as objective response (OR) and progression-free survival (PFS), and have beneficial effects on neurocognitive function (NCF) are of clinical benefit to these patients. We evaluated neurocognitive changes across time in 167 patients with recurre...

Bevacizumab Improves Quality of Life in Patients with Recurrent Glioblastoma

Objective. To quantify the benefits in survival and quality of life in patients receiving bevacizumab (BEV) for recurrent glioblastoma (GBM). Methods. This is a retrospective study of 40 adult patients with recurrent GBM treated between 2005 and 2009 at a single institution. All patients had initial treatment with surgery, radiation, and concurrent temozolomide, then monthly temozolomide. Over ...

Bevacizumab for the Treatment of Recurrent Glioblastoma

Despite advances in upfront therapy, the prognosis in the great majority of patients with glioblastoma (GBM) is poor as almost all recur and result in disease-related death. Glioblastoma are highly vascularized cancers with elevated expression levels of vascular endothelial growth factor (VEGF), the dominant mediator of angiogenesis. A compelling biologic rationale, a need for improved therapy,...

Bevacizumab for recurrent glioblastoma multiforme

evaluation of fat atrophy in patients with dermis fat graft of orbit by ct-scan

چکیده ندارد.